首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Endogenous inspired biomineral-installed hyaluronan nanoparticles as pH-responsive carrier of methotrexate for rheumatoid arthritis
【24h】

Endogenous inspired biomineral-installed hyaluronan nanoparticles as pH-responsive carrier of methotrexate for rheumatoid arthritis

机译:内源激发的生物素安装的透明质酸纳米粒子作为甲氨蝶呤的pH响应载体,用于类风湿性关节炎

获取原文
获取原文并翻译 | 示例
           

摘要

Methotrexate (MTX), an anchor drug for rheumatoid arthritis (RA), has been suffered from refractoriness and high toxicity limiting effective dosage. To mitigate these challenges, the ability to selectively deliver MTX to arthritis tissue is a much sought-after modality for the treatment of RA. In this study, we prepared mineralized nanoparticles (MP-HANPs), composed of PEGylated hyaluronic acid (P-HA) as the hydrophilic shell, 5 beta-cholanic acid as the hydrophobic core, and calciumphosphate (CaP) as the pH-responsivemineral. Owing to the presence of CaP as the diffusion barrier, mineralized HANPs revealed the pH-responsiveness of release kinetics of MTX across neutral to acidic conditions. HANPs were internalized via receptor-mediated endocytosis in macrophages which involvedmolecular redundancy amongmajor hyaladherins, including CD44, stabilin-2, and RHAMM. Following endocytosis, MP-HANPs loaded with doxorubicin revealed pH-dependent demineralization followed by dramatic acceleration of drug release into the cytosol compared to other HANPs. Furthermore, an in vivo study showed a significantly high paw-to-liver ratio of fluorescent intensity after systemic administration of MPHANP-Cy5.5, indicating improved biodistribution of nanoparticles into arthritic paws in collagen-induced arthritis mice. Treatment with MTX-loaded MP-HANPs ameliorated inflammatory arthritis with remarkable safety at high dose of MTX. We highlight the distinct advantages of combining key benefits of biomineralization and PEGylation with HA-based nanoparticles for arthritis-selective targeting, thus suggestingMP-HANPs as a promising carrier of MTX for treatment of RA. (C) 2017 Elsevier B. V. All rights reserved.
机译:甲氨蝶呤(MTX)是类风湿性关节炎(RA)的锚药,已经遭受耐火性和高毒性限制有效剂量。为了减轻这些挑战,选择性地将MTX与关节炎组织递送的能力是一种追捧的ra追踪ra的态度。在该研究中,我们制备了矿化纳米颗粒(MP-HANP),由Pegymated透明质酸(P-HA)作为亲水壳,5β-苯甲酸作为疏水性核心,以及作为pH应答的甲磷酸盐(帽)。由于帽作为扩散屏障的存在,矿化的Hanps揭示了MTX释放动力学的pH-反应性,其中性与酸性条件。汉普通过巨噬细胞的受体介导的内吞作用内化,该巨噬细胞在叙述中涉及透明质的冗余,包括CD44,稳定蛋白-2和RHAMM。在内吞作用之后,含有多柔比星的MP-HANP揭示了pH依赖性的脱矿质,然后与其他HANP相比,将药物释放的剧烈加速到Cytosol。此外,体内研究表明,Mphanp-Cy5.5的全身施用后的荧光强度的显着高的倾盆子比,表明在胶原诱导的关节炎小鼠中改善了纳米颗粒的纳米颗粒生物分布。用MTX加载的MP-HANPS治疗改善炎性关节炎,高剂量的MTX具有显着的安全性。我们突出了与HA基纳米粒子相结合的不同优点,与HA基纳米粒子用于关节炎选择性靶向,因此表明MP-HANPS作为MTX的有充满希望的Ra的载体。 (c)2017年Elsevier B. V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号